MAR 13, 2019 10:46 PM PDT

Combination Immunotherapy Stops Liver Cancer Growth

WRITTEN BY: Nouran Amin

The number of individuals diagnosed with liver cancer is on the rise and current therapies are largely ineffective. However, new preclinical data from the University of California San Diego School of Medicine offers renowned hope. In a study published in Hepatology, a combination immunotherapeutic involving a synthetic double-stranded RNA (dsRNA) polyinosinicpolycytidylic acid (polyIC) with a programmed death-ligand 1 (PD-L1) antibody, was shown to suppress tumor growth in the liver.

"We need to find effective new therapies for this disease. The best drugs in the world only extend a patient's life by an average of three months," said Gen-Sheng Feng, PhD, professor of pathology and molecular biology at UC San Diego and senior author on the paper. "Many immunotherapeutic reagents or protocols are in clinic trials, but very few were based on or justified by solid preclinical data. This study may shift the paradigm in liver cancer treatment, by carefully designing a combination therapy that activates multiple innate and adaptive immune functions within the liver."

In mouse models, the combination of the two reagents effectively inhibited the progression of hepatocellular carcinoma (HCC) and with complete tumor remission and tumor-free survival. The focus of the study was on primary liver cancer, but researchers are also reviewing the effects of the combination immunotherapeutic on metastatic liver cancer and the malignant disease at advanced or terminal stages. Additionally, researchers are examining optimal dosages and are considering other reagent combinations that could be more effective.

"Liver cancer is much more complicated than we thought," says Feng. "We and other researchers found recently that deleting classic oncogenes ironically aggravates liver cancer. The liver has a unique immune-tolerant microenvironment. That's why we haven't been able to develop an effective treatment for liver cancer by blocking oncogenic signaling. Immunotherapy with checkpoint inhibitors, while in many clinical trials worldwide, may have uncertain outcomes due to low or poor response."

Source: University of California of San Diego

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 11, 2020
Drug Discovery & Development
Single Injection Sends Type 2 Diabetes into Remission
SEP 11, 2020
Single Injection Sends Type 2 Diabetes into Remission
Type 2 diabetes affects around 10% of people in the US. Although there is no cure for it, there are some well-known meth ...
SEP 27, 2020
Cannabis Sciences
THC Shows Promise in Treating Severe Cases of COVID-19
SEP 27, 2020
THC Shows Promise in Treating Severe Cases of COVID-19
Over the last few months, various headlines have emerged suggesting the potential for cannabinoids, and in particular, c ...
OCT 13, 2020
Immunology
Early Tips For Cell & Gene Therapy Regulatory Compliance
OCT 13, 2020
Early Tips For Cell & Gene Therapy Regulatory Compliance
Cell and gene therapies hold great promise for improved health outcomes. Now is the time to advance life-saving research ...
OCT 12, 2020
Drug Discovery & Development
Researchers Solve Key Problem for Cancer Immunotherapy
OCT 12, 2020
Researchers Solve Key Problem for Cancer Immunotherapy
Cancer immunotherapies are becoming increasingly promising as a standard-of-care treatment. However, despite their promi ...
OCT 10, 2020
Drug Discovery & Development
Fishnet of Nanoparticles Traps Drug Molecules
OCT 10, 2020
Fishnet of Nanoparticles Traps Drug Molecules
‘Fishnet’ Nanoparticles Traps Drug Molecules A team at Northwestern University have casted a net of nanopart ...
NOV 22, 2020
Cannabis Sciences
Public Believes CBD is Cure-All Despite Lack of Evidence
NOV 22, 2020
Public Believes CBD is Cure-All Despite Lack of Evidence
Many people think that cannabidiol (CBD), a non-psychoactive compound in cannabis, can reduce symptoms from various cond ...
Loading Comments...